Browse > Article

Is the BRCA Germline Mutation a Prognostic Factor in Korean Patients with Early-onset Breast Carcinomas?  

Choi Doo Ho (Departments of Radiation Oncology, Soonchunhyang University, College of Medicine)
Lee Min Hyuk (Departments of Surgery, Soonchunhyang University, College of Medicine)
Haffty Bruce G. (Department of Therapeutic Radiology, Yale University School of Medicine)
Publication Information
Radiation Oncology Journal / v.21, no.2, 2003 , pp. 149-157 More about this Journal
Abstract
Purpose: The purpose of this study was to determine if there were prognostic differences between BRCA related and BRCA non-related Korean patients with early-onset breast carcinomas. Materials and Methods: Sixty women who had developed breast cancers before the age of 40, and who were treated at the Soonchunhyang University Hospital, were studied independently of their family histories. The age range was 18 to 40 with a median of 34.5 years. Lymphocyte specimens from peripheral blood were studied for the heterozygous mutations of BRCA1 and BRCA2 using direct sequencing methods. Immunohistochemistry was peformed on the paraffin-embedded tissue blocks that were available. Results: Eleven deleterious mutations (18.3%, 6 in BRCA1 and 5 in BRCA2) and 7 missense mutations of unknown significance (11.7%), were found among the 60 patients. More than half of the mutation were novel, and were not reported in the database. Most of the BRCA-associated patients had no history of breast cancer. No treatment related failures were observed in the BRCA carriers, with the exception of one patient that had experienced a new primary tumor of the contralateral breast. The seven year relapse free survival rate were 50 and 79% In the BRCA carrier and BRCA negative patients, respectively. Although the expression of estrogen and progesterone receptors were less common, and histological features more aggressive, in the BRCA associated tumors, the outcome of the patients with BRCA mutations was not poorer than that on the patients without deleterious mutations. Conclusion.: Despite the BRCA mutation carriers having adverse prognostic features, the recurrence rate was relatively lower than that in the BRCA non-carrying Korean patients wi4h early-onset breast carcinomas. In addition, although the prevalence of the BRCA mutation in Korean patients was higher than that in white patients, the penetrance of the cancer seemed to be relatively low in Korean women carrying BRCA mutations. A large population based study of the BRCA mutation, with a long-term follow-up of the study patients will be required to confirm these results.
Keywords
BRCA mutation; Early-onset breast carcinoma; Prognostic factor; Korean;
Citations & Related Records
연도 인용수 순위
  • Reference
1 VerhoogLC,BrekelmansCTM,SeynaeveC,etal. Survival and tumor characteristics of Breast cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-321   DOI   ScienceOn
2 Armes JE, Trute L, White D, et al. Distinct molecular pathogenesis ofearly onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population based study. Cancer Res 1999;59:2011-2017   PUBMED
3 Johannson OT, Idvall I, Anderson C, et al. Tumour bilogical features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-371   DOI   ScienceOn
4 Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514   PUBMED
5 Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1392-1402
6 Anglish Breast Cancer Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population- based seriesof breastcancer cases. Br J Cancer 2000; 83:1301-1308   DOI   ScienceOn
7 Papelard H, de BockGH,vanEijkR,etal. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 2000;83:719-724   DOI   ScienceOn
8 Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revised. Cancer Res 1998;58:1588-1592   PUBMED
9 Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breastcarcinoma occurringbeforeage 40years inwomen with andwithoutBRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335- 2345   DOI   ScienceOn
10 Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in BRCA1 breast and ovarian cancer susceptibility gene. J Am Med Assoc 1995; 273:535-541   DOI   ScienceOn
11 PetoJ,CollinsN,BarfootR,etal. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Ins 1999;91:943-949   DOI
12 Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000;18:4053-4059   DOI   PUBMED
13 Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Eng J Med 1996;335: 1413-1416   DOI   ScienceOn
14 Kang HC, KimIJ,ParkJH,etal. Germline mutations of BRCA1 and BRCA2 in Korean breast families. Hum Mutat 2002;20:235-239   PUBMED
15 Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathologic features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 2001; 7:1739-1742   PUBMED
16 Johannesdottir G, Gudmundsson J, Berthorsson JT, et al. High prevalence of the 999del5 mutations in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-3665   PUBMED
17 ChabnerE,Nixon A,Gelman R, et al. Familyhistory and treatment outcome in young women after breast-conserving surgery and radiation therapyfor early-stage breast cancer. J Clin Oncol 1998;16:2045-2051   DOI
18 Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F , Naguchi T, Baily C. Germline mutation at BRCA1 affects the histologic grade in hereditary breast cancer. Cancer Res 1996;56:471-474   PUBMED
19 Wooster R, BignellG,Lancaster J, et al. Identification of the breastcancersusceptibilitygeneBRCA2. Nature 1995;378:789-792   DOI   ScienceOn
20 Clause EB, Schildkraut JM, ThompsonWB. The genetic attributable risk ofbreastand ovariancancer.Cancer 1996; 77:2318-2324   DOI   ScienceOn
21 Loman N,Johannson O, Kristoffersson U,OlssonH,Borg A. Family history ofbreast and ovarian cancers and BRCA1 and BRCA2 mutations inapopulation-based series of early-onset breast cancer. J Natl Cancer Ins 2001;93: 1215-1223   DOI   ScienceOn
22 Verhoog LC, Bern EM,Brekelmans CT, et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 2000;18:119-124
23 Southey MC, Tesoriero AA, Anderson CR, et al. BRCA1 mutations and other sequence variations in a population- based sample ofAustralianwomenwith breast cancer. Br J Cancer 1999;79:34-39   DOI   ScienceOn
24 Thorlacius S,SigurdssonS,BjarnadottirH,etal. Study of a single BRCA2mutation with high carrierfrequency in a small population. Am J Hum Genet 1997;60:1079-1084   PUBMED
25 Johannson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population- based study from southern Sweden. J Clin Oncol 1998; 16:397-404   DOI
26 Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998; 47:129-136   DOI   ScienceOn
27 ParkinDM,WhelanSL, Ferlay J, etal. Cancer incidence in five continents. IARC Scientific Publications No. 143. Lyon: IARC, 1997
28 Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000;36:1200-1208   DOI   ScienceOn
29 MatsudaML,LiedeA,KwanE,etal. BRCA1andBRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 2002;98:596-603   DOI   ScienceOn
30 Struewing JP,HangeP,WacholderS. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997:336:1401-1408
31 Ford D, Easton DF, Stratton M, et al. Genetic heteogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689   DOI   ScienceOn
32 Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187   DOI   ScienceOn
33 Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among AshkenaziJewishindividual is approximately 1%.Nat Genet 1996;14:188-190   DOI   ScienceOn
34 Sng JH, Chang J, Feroze F, et al. The prevalence of BRCA1 mutations in Chinesen patients with early onset breast cancer and affected relatives. Br J Cancer 2000; 82:538-542   DOI   ScienceOn
35 RobsonM, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642- 1649   DOI
36 Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71   DOI   PUBMED
37 NoguchiS, Kasugai T,MikiY,FukutomiT,EmiM,Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2- associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200-2205   DOI   ScienceOn